Pancreatic Cancer Research

ResearcherFred Hutch Cancer CenterNo recent work listed

Michela Capello

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5810-6375; OpenAlex author ID A5085032154. Sources: OpenAlex.

Their work

Papers
21 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
68
Papers, trials and grants by year

2011: 2 papers · 2012: 2 papers · 2013: 3 papers · 2014: none · 2015: 2 papers · 2016: 1 paper · 2017: 2 papers · 2018: 1 paper · 2019: 4 papers · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper

Papers 21

  1. CES2 sustains HNF4α expression to promote pancreatic adenocarcinoma progression through an epoxide hydrolase-dependent regulatory loop. First author DOI 10.1016/j.molmet.2021.101426↗
  2. IL17A critically shapes the transcriptional program of fibroblasts in pancreatic cancer and switches on their protumorigenic functions. Co-author DOI 10.1073/pnas.2020395118↗
  3. CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diabetes. Co-author DOI 10.1200/po.19.00330↗
  4. Immune-Complexome Analysis Identifies Immunoglobulin-Bound Biomarkers That Predict the Response to Chemotherapy of Pancreatic Cancer Patients. Co-author DOI 10.3390/cancers12030746↗
  5. Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity. Co-author DOI 10.1038/s41467-018-08109-6↗
  6. Measuring human carboxylesterase 2 activity in pancreatic cancer patient-derived xenografts using a ratiometric fluorescent chemosensor. Co-author DOI 10.1039/c9sc00283a↗
  7. A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer. Co-author DOI 10.1093/jnci/djy126↗
  8. Integrative Analysis of Novel Metabolic Subtypes in Pancreatic Cancer Fosters New Prognostic Biomarkers. Co-author DOI 10.3389/fonc.2019.00115↗
  9. Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients. Co-author DOI 10.1093/annonc/mdx542↗
  10. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. Co-author DOI 10.1093/jnci/djw266↗
  11. Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis. Co-author DOI 10.1186/s13045-016-0385-8↗
  12. Prognostic and Functional Significance of MAP4K5 in Pancreatic Cancer. Co-author DOI 10.1371/journal.pone.0152300↗
  13. Phosphorylated alpha-enolase induces autoantibodies in HLA-DR8 pancreatic cancer patients and triggers HLA-DR8 restricted T-cell activation. Co-author DOI 10.1016/j.imlet.2015.06.008↗
  14. Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1093/jnci/djv132↗
  15. Mass spectrometric analysis reveals O-methylation of pyruvate kinase from pancreatic cancer cells. First author DOI 10.1007/s00216-013-6880-7↗
  16. Towards pancreatic cancer diagnosis using EIS biochips. Co-author DOI 10.1039/c2lc41127j↗
  17. Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models. Co-author DOI 10.1186/1756-8722-6-67↗
  18. MS analysis reveals O-methylation of L-lactate dehydrogenase from pancreatic ductal adenocarcinoma cells. First author DOI 10.1002/elps.201200017↗
  19. Proteomic analysis reveals Warburg effect and anomalous metabolism of glutamine in pancreatic cancer cells. First author DOI 10.1021/pr2009274↗
  20. Circulating autoantibodies to phosphorylated α-enolase are a hallmark of pancreatic cancer. Co-author DOI 10.1021/pr100213b↗
  21. Proteomic analysis of pancreatic ductal adenocarcinoma cells reveals metabolic alterations. First author DOI 10.1021/pr101179t↗

Closest collaborators

The 25 strongest of 68 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Samir Hanash · 11 shared papers, 2015–2022 · strength 0.82
  2. Francesco Novelli · 12 shared papers, 2011–2021 · strength 0.60
  3. Anirban Maitra · 8 shared papers, 2015–2022 · strength 0.54
  4. Matthew H. G. Katz · 7 shared papers, 2015–2022 · strength 0.47
  5. Jason B. Fleming · 5 shared papers, 2015–2022 · strength 0.40
  6. Jody V. Vykoukal · 4 shared papers, 2019–2022 · strength 0.33
  7. Ya’an Kang · 3 shared papers, 2019–2022 · strength 0.30
  8. Leonidas E. Bantis · 4 shared papers, 2017–2020 · strength 0.27
  9. Johannes Francois Fahrmann · 3 shared papers, 2019–2022 · strength 0.26
  10. Huamin Wang · 3 shared papers, 2016–2022 · strength 0.24
  11. Ziding Feng · 3 shared papers, 2019–2020 · strength 0.22
  12. Paola Cappello · 4 shared papers, 2011–2021 · strength 0.21
  13. Giorgia Mandili · 3 shared papers, 2013–2020 · strength 0.20
  14. Mayrim V. Rios Perez · 2 shared papers, 2020–2022 · strength 0.19
  15. Ehsan Irajizad · 2 shared papers, 2020–2022 · strength 0.19
  16. David Roife · 2 shared papers, 2020–2022 · strength 0.19
  17. Laura R. Prakash · 2 shared papers, 2020–2022 · strength 0.19
  18. Paul J. Chiao · 2 shared papers, 2020–2022 · strength 0.19
  19. Randall E. Brand · 3 shared papers, 2017–2019 · strength 0.19
  20. Francesca Cordero · 2 shared papers, 2019–2020 · strength 0.18
  21. Laura Follia · 2 shared papers, 2019–2020 · strength 0.18
  22. Rosella Spadi · 2 shared papers, 2019–2020 · strength 0.18
  23. Aldo Scarpa · 3 shared papers, 2011–2021 · strength 0.15
  24. Weidong Zhou · 5 shared papers, 2011–2013 · strength 0.15
  25. Lorenzo Piemonti · 4 shared papers, 2011–2013 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.